No Data
No Data
Frontier Biotech (688221.SH): Selling part of the equity of a wholly-owned subsidiary and passively forming external borrowings and guarantees.
Gelonghui October 10th, Front Biosciences (688221.SH) announced that the company holds 100% equity of Sichuan Front Biosciences Co., Ltd. (referred to as Sichuan Front) through its wholly-owned subsidiary Shanghai Qianyan Jianling Biotechnology Co., Ltd. (referred to as Shanghai Jianling); and as the investment subject of Sichuan Front, it has invested in and built a high-end polypeptide active pharmaceutical ingredient production base in Jintang County, Chengdu City, Sichuan Province. In order to focus on the development of the main business and optimize resource allocation, and based on the premise of locking in Sichuan Front as the future entrusted production party of the company's active pharmaceutical ingredients, the company plans to transfer 70% equity of Shanghai Jianling to Tibet Duorui Pharmaceutical Co., Ltd.
Frontier Biotech 2024 Semi-Annual Report
Frontier Biotech 2024 Semi-Annual Report Summary
Frontline Bio (688221.SH) released its performance for the first half of the year, with a net loss of 0.16 billion yuan.
Frontier Biotech (688221.SH) released its 2024 semi-annual report, with a revenue of 5 billion yuan during the reporting period...
Frontier Biotech (688221.SH): gradually launching pilot clinics for the prevention of exposure to Ecnotin in Shanghai and other areas.
On July 8th, Gelunhui reported that Front Bio(688221.SH) stated on the investor interaction platform that currently there are 0.1-0.15 million new HIV infections in China each year, more than 90% of which are transmitted through sexual activity. MSM (men who have sex with men) and high-risk heterosexual groups are both high-risk groups that urgently need to raise awareness of prevention. Timely PEP measures can help reduce HIV transmission. In the future, as the awareness of prevention and medication knowledge for high-risk groups improves after exposure, the market for HIV post-exposure prophylaxis medication will gradually open up. Ekkoning, as a long-acting anti-HIV injection, is a new drug in the field of AIDS prevention.
Frontier Biotechnologies Inc.'s (SHSE:688221) Biggest Owners Are Individual Investors Who Got Richer After Stock Soared 18% Last Week
No Data
No Data